Clinical Trials
Study Title:
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First Line Treatment for Patients with Metastatic EGFR Mutant Non Small Cell Lung Cancer (NSCLC)
|
For more information about the trial above please contact the study team:
|